Navigation Links
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/13/2013

00 p.m. Pacific Time with management to discuss results from the meeting as well as financial results for the first quarter and provide a general corporate update.

About Anthera PharmaceuticalsAnthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.  Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
2. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
3. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
6. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
7. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
8. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
9. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
11. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  In part four of ... hospital pharmacy as a strategic asset, Mary Baxter, ... for Cardinal Health,s Innovation Delivery Solutions business, discusses how ... both hospitals and patients. "Every hospital pharmacist ... of their job in a value-based healthcare world," Baxter ...
(Date:8/29/2014)... DUBLIN , August 29, 2014 ... management and collaboration software has announced a major new ... services, founded by renowned pathology expert, Dr. Marius ... advance of the 26th European Congress of Pathology which ... in the ExCeL Arena, London ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: North America Aesthetic Lasers and ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North America ... 2020 Summary GlobalData,s new report, "North ... to 2020", provides key market data on the ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... May 6 Vanda Pharmaceuticals Inc. (Nasdaq: ... Drug Administration (FDA) has granted marketing approval of Fanapt(TM) ... schizophrenia. The approval was supported by two placebo-controlled Phase ... control in patients with schizophrenia, as well as safety ...
... provide important insight for physicians in treating heart attack ... BSX ) today welcomed the publication of ... issue of the New England Journal of Medicine. ... Foundation with research grant support from Boston Scientific and ...
Cached Medicine Technology:FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 2FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 3FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 4FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 5FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 6FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia 7Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 2Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 3Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 4Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine 5
(Date:8/30/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:8/30/2014)... One of the most recent dietary trends ... diet. Originally meant for sufferers of gluten intolerance and celiac ... who are looking to get healthier by simply consuming foods ... kind of information erroneous, it also exposes those same consumers ... a drastic change in their food consumption habits. ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The new review ... program was created by Karen Brimeyer, who wanted to make ... , This guide is now easy to find in ... download. In this guide, the author of the new method ... , Daily Gossip writes in its review that the ...
(Date:8/30/2014)... 30, 2014 August 28th, 2014: ... in our society and the toll that takes on ... vital that continuing education for physical therapists addresses this ... physical therapists help others, Hands-On Seminars is offering discounts ... , Three learning styles are available to fit the ...
(Date:8/30/2014)... NJ (PRWEB) August 30, 2014 Ms. Meriwether’s ... her. She certainly has an impressive resume to boost. ... Miss USA in 2012. However, she’s also a two ... Grad student. Nana trained for the 2008 Olympics and ... Miss USA website, “This six-foot beauty from Potomac, Maryland is ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:NJ Top Dentists Announces Cover Model for the Healthy Living: Top Dentists Issue 2
... Ind., April 14 Conseco, Inc. (NYSE:,CNO) ... promoted to vice president,enterprise risk management, reporting ... actuary. Mr. Bischof is responsible for overseeing ... conjunction,with Conseco,s Enterprise Risk Management Committee., ...
... April 14 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ), ... and audio web cast on Wednesday, April 30, 2008,at ... release of its,financial results for the first quarter ended ... 6:30 a.m. ET on Wednesday,April 30, 2008., To ...
... male hormone in the morning made more money , , MONDAY, ... finds that financial traders who wake up with high levels ... that day, probably because they feel more daring. , ... stress hormone cortisol tend to be more cautious. , "We ...
... The Pharmaceutical Care,Management Association (PCMA) issued the ... New York Times on skyrocketing biotech prices:, ... and will,spend $100 billion within a few years. ... because they don,t face generic competition once their,patents ...
... Cogdell Spencer,Inc. (NYSE: CSA ) announced today that ... on Monday, May 5, 2008. Cogdell Spencer,Inc. invites you ... May 6, 2008 at 10:00 a.m. (Eastern Time). The ... or (412) 858-4600,(international). In addition, the conference call can ...
... that hypertension should still be treated , , MONDAY, April ... are less likely to have headaches than those with ... one headache expert cautions that the new research does ... or stop taking their blood pressure medications. , The ...
Cached Medicine News:Health News:Testosterone Levels Among Financial Traders Affect Performance 2Health News:Testosterone Levels Among Financial Traders Affect Performance 3Health News:Cogdell Spencer Inc. Announces First Quarter Earnings Release and Conference Call Notice 2Health News:High Blood Pressure May Be Buffer Against Headaches 2Health News:High Blood Pressure May Be Buffer Against Headaches 3
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
... bags are part of the Freedom ... of leg bags, kits, and accessories ... of our customers. These leg bags ... constructed of 100% latex-free soft, textured ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: